Celularity Inc. (CELU) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Celularity Inc. is a regenerative and cellular medicines company focused on aging-related diseases, operating through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company is an emerging growth company and a smaller reporting company. On February 28, 2024, the company effected a 1-for-10 reverse stock split; all share data is adjusted to reflect this.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Net Revenues | $9.3 million | $3.8 million | $36.1 million | $10.7 million |
| Net Loss | $(16.1) million | $(93.9) million | $(44.6) million | $(205.8) million |
| Loss Per Share (Basic/Diluted) | $(0.73) | $(4.98) | $(2.05) | $(11.86) |
| Cash and Cash Equivalents | $0.1 million | $0.2 million | $0.1 million (End of Period) | $0.3 million (End of Period) |
| Total Debt (Short-Term) | $42.6 million | $39.2 million | $42.6 million | $39.2 million |
| Accumulated Deficit | $(886.4) million | $(851.3) million | $(886.4) million | $(851.3) million |
Liquidity: As of September 30, 2024, the company held $0.1 million in unrestricted cash and $10.2 million in restricted cash. Total current liabilities were $76.2 million, significantly exceeding current assets of $14.5 million.
Material Changes vs. Prior Period
- Revenue Growth: Q3 2024 revenue increased 145.5% year-over-year, driven by a $3.9 million increase in "License, royalty and other" revenue (primarily Rebound distributor sales) and a $1.7 million increase in product sales (Biovance 3L and Rebound).
- Expense Reduction: Operating expenses decreased significantly in Q3 2024 compared to Q3 2023 ($20.8M vs $103.0M). This improvement is largely due to the absence of non-recurring charges in the current period, specifically the $82.7 million goodwill impairment and $243,000 in software cease-use costs recorded in Q3 2023.
- R&D Efficiency: Research and development expenses decreased 24.5% in Q3 2024 due to lower personnel costs and the discontinuation of certain clinical trials.
- Debt Restructuring: The company repaid the Yorkville Pre-Paid Advance Agreement in full in January 2024. It subsequently entered into a new $3.15 million convertible promissory note with Yorkville and a $15.0 million bridge loan with Resorts World Inc (RWI).
Guidance, Outlook, Risks, and Contingencies
Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. The company has incurred significant losses since inception, has an accumulated deficit of $886.4 million, and has insufficient unrestricted cash to fund operations for the next 12 months. Additional capital is required to meet obligations, including approximately $46.1 million in debt due within one year.
Nasdaq Compliance: The company is currently non-compliant with Nasdaq Listing Rule 5250(c)(1) due to the late filing of this Q3 2024 report. It has 60 days to submit a plan to regain compliance; failure to do so could result in delisting.
Debt Covenants and Defaults:
- Multiple debt instruments (RWI, C.V. Starr, Yorkville) are subject to forbearance agreements.
- Default interest rates (16% to 18%) are accruing on several loans due to missed interest payments or failure to file registration statements.
- The Yorkville SEPA is currently inactive because the required resale registration statement has not been filed.
Legal Proceedings:
- Palantir: Arbitration settled in June 2024 with a payment of $3.5 million and issuance of shares.
- Evolution Biologyx: Litigation ongoing to recover ~$2.35 million in unpaid invoices.
- False Claims Act: A Civil Investigative Demand regarding Medicare/Medicaid claims for Interfyl is in preliminary stages.
Subsequent Events: On October 9, 2024, the company acquired the Rebound product line from Sequence LifeScience for $5.5 million. On November 25, 2024, the company entered into an agreement to sell up to $1.0 million in unsecured senior convertible notes.
Investor Verification Checklist
- Cash Runway: Verify the timeline for securing additional financing given the $0.1 million unrestricted cash balance and $46 million in near-term debt obligations.
- Nasdaq Status: Monitor the company's ability to submit a compliance plan to Nasdaq within 60 days to avoid delisting.
- Debt Default Risk: Assess the likelihood of lenders enforcing remedies under forbearance agreements given the accrual of default interest rates.
- Revenue Sustainability: Confirm the durability of the revenue spike from Rebound sales and the impact of the October 2024 acquisition on future margins.
- Internal Controls: Note the material weaknesses in internal controls over financial reporting, which contributed to late filings and ineffective disclosure controls.